PMDA drug package insert
注射用レザフィリン100mg
PMDA Prescription drug · Meiji Seika ファルマ株式会社 · package insert Aug 25, 2026
Key facts
| Brand names | 注射用レザフィリン100mg |
|---|---|
| Nonproprietary names | タラポルフィンナトリウム |
| Companies | 製造販売元／Meiji Seika ファルマ株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 光線力学的療法用剤 |
| Therapeutic category codes | 874299 |
| YJ codes | 4299404D1028 |
| Approval numbers | 21500AMZ00509000 |
| Package insert edition | 第2版 |
| Package insert date | Aug 25, 2026 |
| PMDA document key | 780009_4299404D1028_1 |
| PMDA company code | 780009 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: